The Dawn of AI in Prostate Cancer Care

A powerful new ally is emerging in cancer care: artificial intelligence (AI). In the ever-evolving landscape of prostate cancer care, experts believe AI is rapidly becoming an integral part of the prostate cancer journey, offering innovative solutions from diagnosis to treatment planning.

This issue of CURE offers an insightful look into AI’s exciting potential, as explained by leading experts in the field. From the initial stages of detection to the complexities of treatment planning and beyond, AI is showing remarkable promise in augmenting clinicians’ capabilities.

“AI is definitely being folded into different levels of the entire journey for patients,” Dr. Soroush Rais-Bahrami, of Wake Forest University School of Medicine in Winston-Salem, North Carolina, says in our cover story.

For example, a UCLA-led study demonstrated AI’s ability to accurately predict seminal vesicle invasion, which is a crucial factor in determining the aggressiveness of a patient’s disease, guiding treatment decisions. Further, AI is making inroads into the realm of treatment itself, from enhancing the precision of robotic surgery to guiding targeted therapies like transurethral ultrasound ablation.
Although challenges around data privacy and the integration of AI into clinical workflows remain, our experts appear optimistic that AI will usher in a new era of personalized and effective prostate cancer care.

“Understanding each clinical case and personalizing treatment algorithms, decision-making [and] patient counseling is going to be key, and that’s where the nuances of AI will most likely normalize some of the personalization that was largely based on clinician and provider expertise,” Rais-Bahrami adds.

Also in this issue, we highlight results from a trial designed to evaluate personalized therapeutic vaccines among patients with kidney cancer, of which nine had successful anticancer immune responses and were cancer free approximately three years later. As part of CURE's “Speaking Out” video series, Dr. David Braun, from Yale School of Medicine in New Haven, Connecticut, spoke of the trial, its findings and where the field is headed next.

In addition, we offer insight from Dr. Chandler Park, of Norton Cancer Institute in Louisville, Kentucky, on a Food and Drug Administration (FDA) approval for adult patients with muscle-invasive bladder cancer. In particular, he highlights the use of neoadjuvant and adjuvant therapies, as well as what patients should discuss with their providers in the perioperative setting.

For the very latest news in cancer care, be sure to visit us at curetoday.com. We’re committed to bringing you timely updates, including breaking news on FDA approvals, clear explanations of significant cancer developments and much more.

Our mission is to equip you with the knowledge you need to confidently navigate your cancer journey. Within these pages, you’ll discover personal experiences alongside expert perspectives. As always, we hope you find this information both empowering and inspiring. Thank you for being a part of our community.